Literature DB >> 22175760

The economic cost of brain disorders in Europe.

J Olesen1, A Gustavsson, M Svensson, H-U Wittchen, B Jönsson.   

Abstract

BACKGROUND AND
PURPOSE: In 2005, we presented for the first time overall estimates of annual costs for brain disorders (mental and neurologic disorders) in Europe. This new report presents updated, more accurate, and comprehensive 2010 estimates for 30 European countries.
METHODS: One-year prevalence and annual cost per person of 19 major groups of disorders are based on 'best estimates' derived from systematic literature reviews by panels of experts in epidemiology and health economics. Our cost estimation model was populated with national statistics from Eurostat to adjust to 2010 values, converting all local currencies to Euros (€), imputing cost for countries where no data were available, and aggregating country estimates to purchasing power parity-adjusted estimates of the total cost of brain disorders in Europe in 2010.
RESULTS: Total European 2010 cost of brain disorders was €798 billion, of which direct health care cost 37%, direct non-medical cost 23%, and indirect cost 40%. Average cost per inhabitant was €5.550. The European average cost per person with a disorder of the brain ranged between €285 for headache and €30 000 for neuromuscular disorders. Total annual cost per disorder (in billion € 2010) was as follows: addiction 65.7; anxiety disorders 74.4; brain tumor 5.2; child/adolescent disorders 21.3; dementia 105.2; eating disorders 0.8; epilepsy 13.8; headache 43.5; mental retardation 43.3; mood disorders 113.4; multiple sclerosis 14.6; neuromuscular disorders 7.7; Parkinson's disease 13.9; personality disorders 27.3; psychotic disorders 93.9; sleep disorders 35.4; somatoform disorder 21.2; stroke 64.1; and traumatic brain injury 33.0.
CONCLUSION: Our cost model revealed that brain disorders overall are much more costly than previously estimated constituting a major health economic challenge for Europe. Our estimate should be regarded as conservative because many disorders or cost items could not be included because of lack of data.
© 2011 The Author(s). European Journal of Neurology © 2011 EFNS.

Entities:  

Mesh:

Year:  2012        PMID: 22175760     DOI: 10.1111/j.1468-1331.2011.03590.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  333 in total

Review 1.  Utility scores for different health states related to depression: individual participant data analysis.

Authors:  Spyros Kolovos; Judith E Bosmans; Johanna M van Dongen; Birre van Esveld; Dorcas Magai; Annemieke van Straten; Christina van der Feltz-Cornelis; Kirsten M van Steenbergen-Weijenburg; Klaas M Huijbregts; Harm van Marwijk; Heleen Riper; Maurits W van Tulder
Journal:  Qual Life Res       Date:  2017-03-04       Impact factor: 4.147

2.  [Flexibilization of sectoral borders? For].

Authors:  M Lambert
Journal:  Nervenarzt       Date:  2016-03       Impact factor: 1.214

3.  [The German research network for mental disorders].

Authors:  M Bauer; T Banaschewski; A Heinz; I Kamp-Becker; A Meyer-Lindenberg; F Padberg; M A Rapp; R Rupprecht; F Schneider; T G Schulze; H-U Wittchen
Journal:  Nervenarzt       Date:  2016-09       Impact factor: 1.214

Review 4.  Pharmacological and psychosocial management of mental, neurological and substance use disorders in low- and middle-income countries: issues and current strategies.

Authors:  Jair de Jesus Mari; Luís Fernando Tófoli; Cristiano Noto; Li M Li; Alessandra Diehl; Angélica M Claudino; Mario F Juruena
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

5.  Mice Lacking the Serotonin Htr2B Receptor Gene Present an Antipsychotic-Sensitive Schizophrenic-Like Phenotype.

Authors:  Pothitos M Pitychoutis; Arnauld Belmer; Imane Moutkine; Joëlle Adrien; Luc Maroteaux
Journal:  Neuropsychopharmacology       Date:  2015-05-04       Impact factor: 7.853

6.  The association of whole and refined grains consumption with psychological disorders among Iranian adults.

Authors:  Omid Sadeghi; Ammar Hassanzadeh-Keshteli; Hamid Afshar; Ahmad Esmaillzadeh; Peyman Adibi
Journal:  Eur J Nutr       Date:  2017-11-30       Impact factor: 5.614

7.  Healthcare use and costs associated with children's behavior problems.

Authors:  Gabriele Kohlboeck; Marcel Romanos; Christina M Teuner; Rolf Holle; Carla M T Tiesler; Barbara Hoffmann; Beate Schaaf; Irina Lehmann; Olf Herbarth; Sibylle Koletzko; Carl-Peter Bauer; Andrea von Berg; Dietrich Berdel; Joachim Heinrich
Journal:  Eur Child Adolesc Psychiatry       Date:  2013-12-11       Impact factor: 4.785

Review 8.  Targeting BKCa Channels in Migraine: Rationale and Perspectives.

Authors:  Mohammad Al-Mahdi Al-Karagholi; Christian Gram; Cherie Amalie Waldorff Nielsen; Messoud Ashina
Journal:  CNS Drugs       Date:  2020-04       Impact factor: 5.749

Review 9.  Pharmacological targeting of the PDGF-CC signaling pathway for blood-brain barrier restoration in neurological disorders.

Authors:  Sebastian A Lewandowski; Linda Fredriksson; Daniel A Lawrence; Ulf Eriksson
Journal:  Pharmacol Ther       Date:  2016-08-12       Impact factor: 12.310

10.  A comparative assessment of two kynurenic acid analogs in the formalin model of trigeminal activation: a behavioral, immunohistochemical and pharmacokinetic study.

Authors:  Gábor Veres; Annamária Fejes-Szabó; Dénes Zádori; Gábor Nagy-Grócz; Anna M László; Attila Bajtai; István Mándity; Márton Szentirmai; Zsuzsanna Bohár; Klaudia Laborc; István Szatmári; Ferenc Fülöp; László Vécsei; Árpád Párdutz
Journal:  J Neural Transm (Vienna)       Date:  2016-09-14       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.